Treatment strategies that com­bine Revlimid with newer types of anti-tumor agents may be ef­fec­tive for re­lapsed and re­frac­tory mul­ti­ple myeloma, ac­cord­ing to myeloma experts who reviewed re­­sults from stud­ies of these new com­bi­na­tions.

Refractory and re­lapsed mul­ti­ple myeloma is notoriously dif­fi­cult to treat. For every remission period that is achieved, relapse typ­i­cally arises sooner and with greater re­sis­tance to pre­vi­ously used ther­a­pies. These patients have lim­ited op­tions for ther­apy.

In examining trials that tested new ther­a­pies in com­bi­na­tion with Revlimid (lena­lido­mide), the authors of the review hoped to find the po­ten­tial …